SKYE has been in the news 643% more than usual
Nov 24, 2025, 11:32 PM
-36.02%
What does SKYE do
Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
SKYE has been in the news recently: The Schall Law Firm and Rosen Law Firm have initiated class action lawsuits against Skye Bioscience, Inc. for allegedly misleading statements made between November 4, 2024, and October 3, 2025. The Gross Law Firm is also inviting affected shareholders to register for the class action by January 16, 2026.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.